Printer Friendly

Galapagos NV announces new Phase 2 study for filgotinib.

M2 EQUITYBITES-July 5, 2017-Galapagos NV announces new Phase 2 study for filgotinib


Belgium-based biotechnology company Galapagos NV (AMS: GLPG) has launched a new Phase 2 study aimed at examining filgotinib in non-infectious uveitis, the company reported on Wednesday.

The clinical trials will be led by filgotinib collaboration partner Gilead Sciences Inc (NASDAQ: GILD). The Phase 2 study will be a multi-centre, randomised, double-masked, placebo-controlled study to investigate the safety and efficacy of filgotinib in adult patients with active, non-infectious uveitis.

"We are pleased with the initiation of this new Phase 2 study with filgotinib," said Dr Walid Abi-Saab, chief medical officer of Galapagos.

"We look forward to seeing the study results which will show whether filgotinib has the potential to impact signs and symptoms of non-infectious uveitis, a group of inflammatory diseases carrying significant visual morbidities."

Some 110 patients are predicted to be enrolled in the study and will receive filgotinib or placebo for 52 weeks. The primary endpoint is to evaluate the efficacy and safety of filgotinib versus placebo for the treatment of non-infectious intermediate-, posterior- or pan-uveitis.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Clinical report
Date:Jul 5, 2017
Previous Article:Petards Group wins two contracts worth GBP1.5m in total.
Next Article:Real Estate Credit Investments raises GBP23.5m with placement of 14.2 million stock shares at GBP0.165000 per share.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |